Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

105 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Polymorphism of IL-1 receptor antagonist gene: role in cancer.
Sehouli J, Mustea A, Könsgen D, Katsares I, Lichtenegger W. Sehouli J, et al. Anticancer Res. 2002 Nov-Dec;22(6A):3421-4. Anticancer Res. 2002. PMID: 12530098 Review.
RESULTS: A polymorphism is present in intron 2 of the human IL-1RA gene. The IL-1RA allele 2 has an influence on the IL-1RA plasma level. ...Patients with a heterozygosity of allele 2 for IL-1 RA (IL-RA1/2) have an increased risk of cervical cancer. There are negati …
RESULTS: A polymorphism is present in intron 2 of the human IL-1RA gene. The IL-1RA allele 2 has an influence on the IL-1RA plasma le …
Polymorphism of the IL-8 gene and the risk of ovarian cancer.
Koensgen D, Bruennert D, Ungureanu S, Sofroni D, Braicu EI, Sehouli J, Sümnig A, Delogu S, Zygmunt M, Goyal P, Evert M, Olek S, Biebler KE, Mustea A. Koensgen D, et al. Cytokine. 2015 Feb;71(2):334-8. doi: 10.1016/j.cyto.2014.07.254. Epub 2014 Aug 21. Cytokine. 2015. PMID: 25151495 Clinical Trial.
Ovarian cancer still represents a challenge in gynecological oncology. Most patients are diagnosed in an advanced tumor stage. ...Interleukin 8 (IL-8) is a pro-inflammatory chemokine known for its angiogenetic activity, and is supposedly responsible for tumor-associ …
Ovarian cancer still represents a challenge in gynecological oncology. Most patients are diagnosed in an advanced tumor stage. ...Int …
The Tumor Suppressor MicroRNA-1 Exhibits Restricted Inhibition of Proliferation of Ovarian Cancer Cells.
Stope MB, Hettenbach D, Kaul A, Paditz M, Diesing K, Burchardt M, Zygmunt M, Mustea A, Koensgen D. Stope MB, et al. Anticancer Res. 2016 Jul;36(7):3329-34. Anticancer Res. 2016. PMID: 27354590
One of the micro RNAs, namely miR-1, has been classified as a tumor suppressor, however, preliminary data did not confirm this finding in ovarian cancer (OC) cells. ...Notably, the present study demonstrated a loss of growth-inhibitory functionality of miR-1 by so f …
One of the micro RNAs, namely miR-1, has been classified as a tumor suppressor, however, preliminary data did not confirm this findin …
Expression and localization of e-cadherin in epithelial ovarian cancer.
Koensgen D, Freitag C, Klaman I, Dahl E, Mustea A, Chekerov R, Braicu I, Lichtenegger W, Sehouli J. Koensgen D, et al. Anticancer Res. 2010 Jul;30(7):2525-30. Anticancer Res. 2010. PMID: 20682978
A significant correlation between increased volume of ascites and higher E-cadherin immunoexpression was found in primary OC (p=0.029). ...
A significant correlation between increased volume of ascites and higher E-cadherin immunoexpression was found in primary OC (p=0.029
Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer.
Hefler LA, Mustea A, Könsgen D, Concin N, Tanner B, Strick R, Heinze G, Grimm C, Schuster E, Tempfer C, Reinthaller A, Zeillinger R. Hefler LA, et al. Clin Cancer Res. 2007 Feb 1;13(3):898-901. doi: 10.1158/1078-0432.CCR-06-1008. Clin Cancer Res. 2007. PMID: 17289883
EXPERIMENTAL DESIGN: In the present multicenter study, we examined three common polymorphisms within the VEGF gene (-634G/C, -1154G/A, and -2578C/A) known to be associated with an increased VEGF production in 563 Caucasian patients with ovarian cancer from Austria a …
EXPERIMENTAL DESIGN: In the present multicenter study, we examined three common polymorphisms within the VEGF gene (-634G/C, -1154G/A
Vascular endothelial growth factor gene polymorphisms in ovarian cancer.
Polterauer S, Grimm C, Mustea A, Concin N, Tanner B, Thiel F, Heinze G, Reinthaller A, Zeillinger R, Hefler LA. Polterauer S, et al. Gynecol Oncol. 2007 May;105(2):385-9. doi: 10.1016/j.ygyno.2006.12.021. Epub 2007 Feb 6. Gynecol Oncol. 2007. PMID: 17289129 Clinical Trial.
Expression of IL-10 in patients with ovarian carcinoma.
Mustea A, Könsgen D, Braicu EI, Pirvulescu C, Sun P, Sofroni D, Lichtenegger W, Sehouli J. Mustea A, et al. Anticancer Res. 2006 Mar-Apr;26(2C):1715-8. Anticancer Res. 2006. PMID: 16617566
RESULTS: The concentrations of IL-10 were a median of 9.87 pg/ml (range 7.8 to 500 pg/ml) in the serum and a median of 43.70 pg/ml (range 7.8 to 389.4 pg/ml) in the ascites of the OC patients. ...The cut-off value of 8.0 pg/ml for IL-10 serum levels had a pos …
RESULTS: The concentrations of IL-10 were a median of 9.87 pg/ml (range 7.8 to 500 pg/ml) in the serum and a median of 43.70 p …
Drug-induced Modulation of Heat Shock Protein HSPB1 in an Ovarian Cancer Cell Model.
Stope MB, Wiegank L, Weiss M, Diesing K, Koensgen D, Burchardt M, Zygmunt M, Mustea A. Stope MB, et al. Anticancer Res. 2016 Jul;36(7):3321-7. Anticancer Res. 2016. PMID: 27354589
RESULTS: Incubation with paclitaxel, and with carboplatin significantly reduced cell growth without a definitive increase of intracellular HSPB1 expression. ...CONCLUSION: Despite its current lack of analysis in patient samples, serum soluble HSPB1 may function as a
RESULTS: Incubation with paclitaxel, and with carboplatin significantly reduced cell growth without a definitive increase of intracel …
Interleukin 1 receptor antagonist (IL-1RA) polymorphism in women with cervical cancer.
Mustea A, Sehouli J, Könsgen D, Stengel D, Sofroni D, Lichtenegger W. Mustea A, et al. Anticancer Res. 2003 Mar-Apr;23(2A):1099-102. Anticancer Res. 2003. PMID: 12820354
MATERIALS AND METHODS: In a prospective study we analysed the polymorphism of IL-1RA in 113 women with cervical cancer and 107 with benign diseases. ...CONCLUSION: This data supports the role for allele 2 of the gene encoding for IL1-RA as a genetic determinant of c …
MATERIALS AND METHODS: In a prospective study we analysed the polymorphism of IL-1RA in 113 women with cervical cancer and 107 with b …
Interleukin-1 receptor antagonist gene polymorphism and cancer.
Sehouli J, Mustea A. Sehouli J, et al. Clin Infect Dis. 2002 Jun 1;34(11):1535-6. doi: 10.1086/340530. Clin Infect Dis. 2002. PMID: 12015703 No abstract available.
105 results
Jump to page
Feedback